Navigation Links
Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer

monitis, which occurred at a rate of less than 1 percent.

An update of cardiac function in patients enrolled in the NSABP B-31 trial presented by Priya Rastogi, M.D., of the University of Pittsburgh Cancer Institute (Abstract #513 -- Monday, June 4, 2007, 9:15 a.m. CDT), showed that the five-year cumulative incidence of cardiac events in the Herceptin-containing treatment arm was 3.8 percent, compared to 0.9 percent in the control arm. The cumulative incidence of cardiac dysfunction in the Herceptin arm remained stable, with no increase in cardiac events between year three and year five of follow-up, providing important insights into the long-term cardiac effects of Herceptin.

About Herceptin

Herceptin is a targeted therapeutic antibody treatment for women who have tumors that overexpress the human epidermal growth factor receptor 2 (HER2) protein. HER2-positive breast cancer is an especially aggressive form of the disease that affects approximately one-fourth of women with breast cancer. Research has shown that women with HER2-positive breast cancer have a greater likelihood of recurrence, poorer prognosis, and decreased survival compared to women with HER2-negative breast cancer. Special testing is required to identify women who have HER2-positive breast cancer and who may be candidates for treatment with Herceptin.

Herceptin is the only targeted biologic therapy approved for treatment of HER2-positive breast cancer in the adjuvant and metastatic settings. Herceptin first received FDA approval in September 1998 for use in metastatic breast cancer, as a first-line therapy in combination with paclitaxel and as a single agent in second- and third-line therapy. In clinical trials of patients with HER2-positive metastatic breast cancer, Herceptin, in combination with chemotherapy (paclitaxel), was the first anti-HER2 agent to demonstrate an improvement in survival in a Phase III study. In December 2001, Genentech received FDA approval to inc
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
10. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
11. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)... 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 ... some of our Medicare resources and continue highlighting the success of the prescription drug ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... SPRING, Md., April 19, 2011 The Food and ... the root of misuse, misprescribing, abuse, overdoses, addiction, and ... of these powerful opioids? (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm251830.htm Sign up for e-mail ...
... 19, 2011 Amira Pharmaceuticals, Inc. announced today that ... an orphan drug designation by the U.S. Food and ... Commonly referred to as IPF, this fibrotic disease affects ... "This is an important development for Amira, ...
Cached Medicine Technology:Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis 2
(Date:7/30/2015)... ... July 30, 2015 , ... OSF Healthcare System has been ... Most Wired Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive ... by The Sisters of the Third Order of St. Francis . , Health ...
(Date:7/30/2015)... ... 30, 2015 , ... The connection between a healthy head of hair and a feeling of ... full head of hair can have a devastating impact on the daily life of a ... work place, the consequences of hair loss are not to be taken lightly. , The ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life has created ... With no water needed, the refreshing berry-flavored tablets are the perfect travel companion. ... natural ingredients that may help with body detoxification, protection and hydration,” said Mark ...
(Date:7/30/2015)... ... 30, 2015 , ... Eyepartner is proud to highlight that ... California’s Gaslamp Quarter Plaza for five years this September. , The surveillance ... for any suspicious activity. These cameras are in place to provide inarguable proof ...
(Date:7/30/2015)... ... 2015 , ... The American Telemedicine Association (ATA) is seeking ... exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract over 6,000 ... May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts the world’s ...
Breaking Medicine News(10 mins):Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
... Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- Researchers report ... kicking off puberty in humans, a finding that offers insight ... who suffer from a rare disease that prevents the start ... family whose members have suffered from the disease confirmed that ...
... , WEDNESDAY, Feb. 15 (HealthDay News) -- ... or stroke, peripheral artery disease is often unrecognized and ... scientific statement released Wednesday. Peripheral artery disease is ... and other materials in the blood vessels outside the ...
... California reported the largest decline in drunk-driving deaths of any ... and a $232,000 grant from the California Office of Traffic ... to UC Irvine,s Health Education Center is helping to keep ... College DUI Awareness Program, UCI has organized nine universities into ...
... -- Hospitalization for underage drinking is common in the United ... estimated total cost for these hospitalizations is about $755 million ... also found geographic and demographic differences in the incidence of ... the Journal of Adolescent Health . Of ...
... potential for making medical isotopes with X-rays from a particle ... to the large scale. The Canadian Isotope Project, led by ... Research Council of Canada, and medical researchers in Winnipeg, Ottawa ... production levels with the delivery of a new particle accelerator ...
... TAMPA, Fla. A recent study conducted by researchers at ... in Rochester, Minn., has found that female cancer survivors receiving ... screening and who had never had cancer. The study ... Journal of Clinical Oncology . Researchers surveyed 19,948 women ...
Cached Medicine News:Health News:Gene Linked to Start of Puberty 2Health News:Circulatory Disorder Not Studied Enough in Women, Experts Say 2Health News:UCI leads multicampus collaboration to reward use of designated drivers 2Health News:Mayo Clinic: Hospitalization of US underage drinkers common, costs $755 million a year 2Health News:Canadian Isotope Project enters final stretch 2Health News:Female cancer survivors have 'worse health behaviors' than women with no cancer history 2
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... high throughput primary or backup instrument, ... performance and reliability equal to or ... The advanced technology of the AUTION ... delivers reproducible and accurate results, limiting ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
... Estrone Sulfate (E1S) is the most abundant ... as normal men [1,2]. Estrone Sulfate is ... and has a longer half-life in blood ... generally parallel those of estrone and estradiol, ...
Medicine Products: